New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
07:33 EDTNBSNeoStem awarded two European patents
NeoStem announced the expansion of its intellectual property protection surrounding its CD34 Cell Program in which it is developing therapeutics to address ischemia. AMR-001 is the company's most clinically advanced product candidate in its CD34 Cell Program and is being developed to treat damaged heat muscle following a heart attack. The European Patent Office has notified the company that it has granted patent numbers 1951864 and 2441461 for "Compositions and Methods of Vascular Injury Repair." These represent NeoStem's first granted European patents for its CD34 Cell Program and bring the Program's total worldwide patent coverage to 16 granted and allowed patents. NeoStem announced completion of enrollment in its Phase 2 PreSERVE AMI clinical trial in 4Q13, a randomized, double-blind placebo-controlled study testing AMR-001for the treatment of patients with left ventricular dysfunction following STEMI. Data read out is expected in 2H14 and the company expects to advance the technology into other clinical indications, such as chronic heart failure, traumatic brain injury and/or critical limb ischemia.
News For NBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2015
07:40 EDTNBSNeoStem announces extension of study under grant from CIRM
NeoStem announced the extension of its study under a 2014 Early Translational grant from the California Institute of Regenerative Medicine, or CIRM, for research leading to the development of a treatment for retinal diseases, including macular degeneration and retinitis pigmentosa. Under the $4M grant made to the University of California, Irvine, NeoStem is entitled, through a subaward, to $1M of new funds adding to the original $0.5M awarded. The goals of the research are to generate three-dimensional retinal tissue, to investigate the ability of adult induced pluripotent stem cells to restore sight in rodent models of retinal degeneration and to make eventual preparations for clinical use of the tissue.
April 7, 2015
10:38 EDTNBSNeoStem management to meet with Philadelphia Securities Association
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use